Breakthrough Therapy Status €“ Expedited FDA Regulatory Approval but What About the Payers?

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.436
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation

JAMA - Journal of the American Medical Association
Medicine
2018English

FDA Approval of New Drugs

JAMA - Journal of the American Medical Association
Medicine
2014English

FDA Approval of Obesity Drugs

JAMA - Journal of the American Medical Association
Medicine
2012English

Php357 - Making Sense From Anti-Sense: Lessons in Translating Expedited Regulatory Approval Into Reimbursement and Commercial Success

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Obinutuzumab Breaks Through to FDA Approval

Cancer Discovery
Oncology
2013English

Safety Related Label Changes for New Drugs After Approval in the US Through Expedited Regulatory Pathways: Retrospective Cohort Study

British Medical Journal
Medicine
2017English

Entering a New Era – Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T

2011English

Php221 - Conditional Approval: Are Payers Rewarding These Highly Needed Pharmaceuticals?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php358 - Time-Limited G-Ba Resolutions – A Tool to Appropriately Manage Reimbursement of Innovative Therapies Receiving Expedited Regulatory Approval

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy